GlassScriptPhysician profile
Robert G Naegele
NPI 1356346084
$2,058.27
in general payments reported to CMS, 2019-2025
25 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.27 · 2020: $293 · 2021: $173 · 2022: $383 · 2023: $321 · 2024: $310 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,110.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.73 | 2021-2025 | |
| Allergan, INC. | $187.23 | 2019-2020 | |
| Novo Nordisk INC | $166.14 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $164.91 | 2019-2025 | Fasenra |
| Pfizer INC. | $112.16 | 2023-2025 | |
| Glaxosmithkline, LLC. | $70.12 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $67.61 | 2020-2025 | Spravato |
| Lilly USA, LLC | $64.85 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $54.71 | 2024-2025 | Veozah |
| Actelion Pharmaceuticals US, INC. | $47.17 | 2023-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $39.40 | 2022 | |
| Philips North America LLC | $33.70 | 2020-2024 | (Ck7) Extended Holter |
| Abbott Laboratories | $32.99 | 2021 | |
| Merck Sharp & Dohme LLC | $28.04 | 2021-2025 | Capvaxive, Vaxneuvance, Gardasil 9 |
| Idorsia Pharmaceuticals US INC | $27.39 | 2022-2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $27.03 | 2023-2025 | Cologuard Collection Kit |
| Grifols USA, LLC | $24.19 | 2022 | |
| Hologic Sales and Service, LLC | $18.88 | 2025 | Aptima, Thinprep 2000 Processor |
| Eisai INC. | $17.69 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.92 | 2022 | |
| Esperion Therapeutics, INC. | $15.08 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.62 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.21 | 2023 | Livalo, Seglentis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Naegele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.